Evidence map›Paper›PMID 25356865›Full record

ArticleCell death & disease2014

Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma.

K E McCabe, K Bacos, D Lu, J R Delaney, J Axelrod, M D Potter, M Vamos, V Wong, N D P Cosford, R Xiang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal transduction and targeted therapy · 2024
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Necroptosis in stressed ovary.Journal of biomedical science · 2019
    Review
  20. Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia.Frontiers in cell and developmental biology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

K E McCabeDepartment of Reproductive Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
K BacosDepartment of Reproductive Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
D Lu1] Department of Reproductive Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA [2] Nankai University School of Medicine, Tianjin, China.
J R DelaneyDepartment of Reproductive Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
J AxelrodDepartment of Reproductive Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
M D PotterDepartment of Reproductive Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
M VamosSanford-Burnham Medical Research Institute, La Jolla, CA, USA.
V WongDepartment of Reproductive Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
N D P CosfordSanford-Burnham Medical Research Institute, La Jolla, CA, USA.
R XiangNankai University School of Medicine, Tianjin, China.
D G StupackDepartment of Reproductive Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
University of California, San Diego · USSanford Burnham Prebys Medical Discovery Institute · USNankai University · CN

Funding

UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
Integrins and Caspase 8 in Tumor ProgressionR01CA107263 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI STUPACK, DWAYNE G. · 2005 to 2014
$3.1M
HUMAN GENOME INITIATIVE AND ACCESS TO HEALTH CARER01HG000503 · NHGRI · CASE WESTERN RESERVE UNIVERSITY · PI MURRAY, THOMAS · 1991 to 1992
–
NCI NIH HHS CA107263NCI NIH HHS R01 CA107263NCI NIH HHS T32 CA121938NCI NIH HHS T32CA121938NHGRI NIH HHS U54 HG00503
6 · The paper itself

Abstract

Ovarian cancer patients are typically treated with carboplatin and paclitaxel, but suffer a high rate of relapse with recalcitrant disease. This challenge has fostered the development of novel approaches to treatment, including antagonists of the 'inhibitor of apoptosis proteins' (IAPs), also called SMAC mimetics, as apoptosis-inducing agents whose action is opposed by caspase inhibitors. Surprisingly, IAP antagonist plus caspase inhibitor (IZ) treatment selectively induced a tumor necrosis factor-α (TNFα)-dependent death among several apoptosis-resistant cell lines and patient xenografts. The induction of necroptosis was common in ovarian cancer, with expression of catalytically active receptor-interacting protein kinase-3 (RIPK3) necessary for death, and in fact sufficient to compromise survival of RIPK3-negative, necroptosis-resistant ovarian cancer cells. The formation of a necrosome-like complex with a second critical effector, receptor-interacting serine-threonine kinase-1 (RIPK1), was observed. RIPK1, RIPK3 and TNFα were required for the induction of death, as agents that inhibit the function of any of these targets prevented cell death. Abundant RIPK3 transcript is common in serous ovarian cancers, suggesting that further evaluation and targeting of this RIPK3-dependent pathway may be of clinical benefit.

Indexed as

ApoptosisAutocrine CommunicationCisplatinDrug Resistance, NeoplasmFemaleHumansInhibitor of Apoptosis ProteinsMutationNecrosisOligopeptidesOvarian NeoplasmsPhenotypeProtease InhibitorsReceptor-Interacting Protein Serine-Threonine KinasesTranscription, GeneticTumor Necrosis Factor-alphabenzyloxycarbonyl-valyl-alanyl-aspartic acidCisplatinInhibitor of Apoptosis ProteinsOligopeptidesProtease InhibitorsReceptor-Interacting Protein Serine-Threonine KinasesRIPK1 protein, humanRIPK3 protein, humanTumor Necrosis Factor-alpha

Identifiers

PMID25356865
PMCPMC4237265
OpenAlexW1978826128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.